ATAGI Targeted Review 2022: Vaccination for prevention of herpes zoster in Australia

Authors

  • Yuanfei Anny Huang National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia
  • Jean Li-Kim-Moy National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  • Sanjay Jayasinghe National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  • Clayton Chiu National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  • Kristine Macartney National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia
  • Bette Liu National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; School of Population Health, University of New South Wales, Sydney, Australia
  • Penelope Burns Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory, Australia; Department of General Practice, School of Medicine, Western Sydney University, Sydney, Australia
  • Michelle Giles Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia; Department of Infectious Diseases, University of Melbourne, Melbourne, Victoria, Australia
  • Nigel Crawford Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Immunisation Services, Royal Children’s Hospital, Melbourne, Victoria, Australia; Infection and Immunity, Murdoch Children’s Research Institute and Department of Paediatrics, University of Melbourne, Victoria, Australia

DOI:

https://doi.org/10.33321/cdi.2023.47.21

Keywords:

Herpes zoster, herpes zoster vaccine

Abstract

This Review was updated on 3 May 2023 to include an Acknowledgments section omitted from the original text.

In November 2016, herpes zoster (HZ) vaccination for older adults, using the live-attenuated zoster vaccine (Zostavax; ZVL) was added to the Australian National Immunisation Program (NIP) with the aim of reducing morbidity from HZ and its complications, particularly for people at increased risk. Prior to the program, there were on average 5.6 cases of HZ per 1,000 persons annually in Australia, with highest risk of disease in older and in immunocompromised people. The burden of complications of HZ, such as post-herpetic neuralgia (PHN), was also highest in older and immunocompromised groups.
No formal comprehensive program evaluation has been undertaken since program commencement. This review examined published literature and available vaccine administration data to summarise the evidence and considerations underpinning current use of HZ vaccines and potential future program directions in Australia.
There have been modest reductions in the incidence of HZ and its complications since program introduction. However, five years into the program, challenges remain, including suboptimal vaccine coverage and significant safety concerns arising from inadvertent use of ZVL in immunocompromised people, who are contraindicated to receive this vaccine. This reduces opportunities to offset the burden of HZ-related disease.
The recombinant subunit zoster vaccine (Shingrix; RZV), first registered in Australia in 2018, became available on the Australian market in June 2021. This vaccine has higher efficacy than ZVL and, as a non-live vaccine, can be used in both immunocompetent and immunocompromised people. RZV has potential to address the unmet needs of at-risk population groups. However, it has not yet demonstrated cost-effectiveness for inclusion as a funded vaccine under the NIP.
The Australian HZ vaccination program has had limited effectiveness in meeting its aim in highest risk groups. Future options and challenges anticipated in using vaccination to reduce the burden of HZ and its complications are discussed in this review.

Downloads

Download data is not yet available.

References

Australian Technical Advisory Group on Immunisation (ATAGI). Zoster (herpes zoster). [Webpage.] Canberra: Australian Government Department of Health and Aged Care, Australian Immunisation Handbook; 2020. Available from: https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/zoster-herpes-zoster.

National Center for Immunization and Respiratory Diseases. Shingles (Herpes Zoster). [Internet.] Atlanta: United States Department of Health and Human Services, Centers for Disease Control and Prevention(CDC); 5 October 2020. Available from: https://www.cdc.gov/shingles/hcp/clinical-overview.html.

National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in varicella vaccination practice in Australia. Sydney: NCIRS; 2018. Available from: https://www.ncirs.org.au/sites/default/files/2018-11/Varicella-history-July-2018.pdf.

ATAGI. Clinical advice. Statement on the clinical use of zoster vaccines in older adults in Australia. Version 2.1. Issue date: 26 April 2022. Canberra: Australian Government Department of Health and Aged Care; 26 April 2022. Available from: https://www.health.gov.au/resources/publications/statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia.

Sheel M, Beard F, Quinn H, Dey A, Kirk M, Koehler A et al. Australian vaccine preventable disease epidemiological review series: varicella-zoster virus infections, 1998–2015. Commun Dis Intell (2018). 2018;42:S2209-6051(18)00002-7.

MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing trends of herpes zoster in Australia. PLoS One. 2015;10(4):e0125025. doi: https://doi.org/10.1371/journal.pone.0125025.

Australian Institute of Health and Welfare (AIHW). The burden of vaccine preventable diseases in Australia. Canberra: Australian Government, AIHW; 1 November 2019. Available from: https://www.aihw.gov.au/reports/immunisation/the-burden-of-vaccine-preventable-diseases/summary.

Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, Orrico-Sánchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014. BMC Infect Dis. 2020;20(1):905. doi: https://doi.org/10.1186/s12879-020-05648-6.

Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi: https://doi.org/10.1136/bmjopen-2014-004833.

Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clinic Proc. 2011;86(2):88–93. doi: https://doi.org/10.4065/mcp.2010.0618.

Therapeutic Goods Administration (TGA). Public Summary: ZOSTAVAX zoster virus vaccine. [Document.] Canberra: Australian Government Department of Health and Aged Care, TGA; 2021.

TGA. Public Summary: SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen vaccine. [Document.] Canberra: Australian Government Department of Health and Aged Care, TGA; 2021.

Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84. doi: https://doi.org/10.1056/NEJMoa051016.

Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–8. doi: https://doi.org/10.1093/cid/cir970.

Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.

Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–9. doi: https://doi.org/10.1093/cid/ciu918.

Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥ 60 Years. J Infect Dis. 2016;213(12):1872–5. doi: https://doi.org 10.1093/infdis/jiw047.

McDonald BM, Dover DC, Simmonds KA, Bell CA, Svenson LW, Russell ML. The effectiveness of shingles vaccine among Albertans aged 50 years or older: a retrospective cohort study. Vaccine. 2017;35(50):6984–9. doi: https://doi.org/10.1016/j.vaccine.2017.10.067.

Klein NP, Bartlett J, Fireman B, Marks MA, Hansen J, Lewis E et al. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine. 2019;37(36):5422–7. doi: https://doi.org/10.1016/j.vaccine.2019.07.004.

Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW et al. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine. 2017;35(52):7231–9. doi: https://doi.org/10.1016/j.vaccine.2017.11.013.

TGA. Zostavax safety advisory - careful assessment and screening for immunocompromise essential before administration of Zostavax. [Internet.] Australian Government Department of Health and Aged Care, TGA; 17 February 2022. Available from: https://www.tga.gov.au/alert/zostavax.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi: https://doi.org/10.1056/NEJMoa1501184.

Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi: https://doi.org/10.1056/NEJMoa1603800.

Pharmaceutical Benefits Advisory Committee (PBAC). Public Summary Document – November 2018 PBAC Meeting: RECOMBINANT VARICELLA ZOSTER VIRUS VACCINE, Injection, Shingrix, GlaxoSmithKline. Canberra: Australian Government Department of Health and Aged Care; November 2018. Available from: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-11/Varicella-Zoster-Virus-psd-november-2018.

Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation – a randomized clinical trial. JAMA. 2019;322(2):123–33. doi: https://doi.org/10.1001/jama.2019.9053.

Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000. doi: https://doi.org/10.1016/S1473-3099(19)30163-X.

Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C et al. The adjuvanted recombinant zoster vaccine confers long-term protection against Herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74(8):1459–67. doi: https://doi.org/10.1093/cid/ciab629.

NCIRS. Summary of findings: recombinant herpes zoster vaccine (Shingrix) compared with placebo for immunocompetent older adults. Sydney: NCIRS; June 2021. Available from: https://www.ncirs.org.au/sites/default/files/2021-07/Shingrix%20vs%20Placebo%20Immunocompetent%20Adults%20GRADE_FINAL.pdf.

NCIRS. GRADE assessment of recombinant herpes zoster vaccine (Shingrix) in immunocompromised older adults compared to placebo. [Internet.] Sydney: NCIRS; June 2021. Available from: https://www.ncirs.org.au/our-work/australian-immunisation-handbook/zoster-grade-assessments.

Forshee RA, United States Food and Drug Administration (FDA). Risk of Guillain-Barré syndrome (GBS) following recombinant zoster vaccine (RZV). Silver Spring: United States Government Department of Health and Human Services, FDA; 25 February 2021. Available from: https://stacks.cdc.gov/view/cdc/107072.

Prosser LA. Projected risks and health benefits of vaccination against herpes zoster and related complications : interim results. Ann Arbor: University of Michigan; 25 February 2021. Available from: https://stacks.cdc.gov/view/cdc/107073.

NCIRS. Summary of findings: Recombinant herpes zoster vaccine (Shingrix) compared with live zoster vaccine (Zostavax) for immunocompetent older adults. Sydney: NCIRS; June 2021. Available from: https://www.ncirs.org.au/sites/default/files/2021-07/Shingrix%20vs%20Zostavax%20Immunocompetent%20Adults%20GRADE_FINAL.pdf.

Tricco AC, Zarin W, Cardoso R, Veroniki AA, Khan PA, Nincic V et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ. 2018;363:k4029. doi: https://doi.org/10.1136/bmj.k4029.

NCIRS. Significant events in zoster vaccination practice in Australia. Sydney: NCIRS; 2021. Available from: https://www.ncirs.org.au/sites/default/files/2021-07/Zoster-history-July%202021.pdf.

NCIRS. Evaluation of the National Shingles Vaccination Program Process and early impact evaluation. Final report. Sydney: NCIRS; 1 March 2019. Available from: https://ncirs.org.au/sites/default/files/2019-04/Shingles%20Program%20Evaluation%20Report_1%20March%202019_Final%20for%20web.pdf.

Australian Government Department of Health and Aged Care. National Immunisation Program: Shingles vaccination catch-up program extended. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 15 October 2021. Available from: https://www.health.gov.au/news/national-immunisation-program-shingles-vaccination-catch-up-program-extended.

Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F. Annual immunisation coverage report 2020. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.60.

Hull B, Hendry A, Dey A, Macartney K, Beard F. Immunisation coverage annual report 2019. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2020.45.18.

Hull B, Hendry A, Dey A, McIntyre P, Macartney K, Beard F. Immunisation coverage annual report 2018. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2020.45.17.

Hull B, Hendry A, Dey A, Macartney K, McIntyre P, Beard F. Exploratory analysis of the first 2 years of adult vaccination data recorded on AIR. Sydney: NCIRS; November 2019. Available from: https://www.ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%20data%20on%20AIR_Nov%202019.pdf.

Lin J, Wood JG, Bernardo C, Stocks NP, Liu B. Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program. Vaccine. 2020;38(20):3646–52. doi: https://doi.org/10.1016/j.vaccine.2020.03.036.

Australian Government Department of Health and Aged Care. Mandatory reporting of National Immunisation Program vaccines to the Australian Immunisation Register began on 1 July 2021. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 8 July 2021. Available from: https://www.health.gov.au/news/mandatory-reporting-of-national-immunisation-program-vaccines-to-the-australian-immunisation-register-began-on-1-july-2021.

Lin J, Dobbins T, Wood JG, Hall JJ, Liu B. Impact of a structured older persons health assessment on herpes zoster vaccine uptake in Australian primary care. Prev Med. 2022;155:106946. doi: https://doi.org/10.1016/j.ypmed.2021.106946.

Litt J, Booy R, Bourke D, Dwyer DE, Leeb A, McCloud P et al. Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine. Hum Vaccin Immunother. 2020;16(12):3081–9. doi: https://doi.org/10.1080/21645515.2020.1754702.

Lin J, Dobbins T, Wood JG, Bernardo C, Stocks NP, Liu B. Impact of a national immunisation program on herpes zoster incidence in Australia. J Infect. 2022;84(4):537–41. doi: https://doi.org/10.1016/j.jinf.2022.01.011.

Lin J, Dobbins T, Wood JG, Bernardo C, Stocks NP, Liu B. Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia. Vaccine. 2021;39(10):1493–8. doi: https://doi.org/10.1016/j.vaccine.2021.01.067.

Alexander KE, Tong PL, Macartney K, Beresford R, Sheppeard V, Gupta M. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine. 2018;36(27):3890–3. doi: https://doi.org/10.1016/j.vaccine.2018.05.078.

ATAGI. Table. Live shingles vaccine (Zostavax) screening for contraindications. [Webpage.] Australian Government Department of Health and Aged Care, Australian Immunisation Handbook; 15 October 2021. Available from: https://immunisationhandbook.health.gov.au/resources/handbook-tables/table-live-shingles-vaccine-zostavax-screening-for-contraindications.

TGA. Zostavax vaccine. Safety advisory - not to be used in patients with compromised immune function. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 7 March 2017. Available from: https://www.tga.gov.au/alert/zostavax-vaccine.

TGA. Zostavax vaccine. Safety advisory - not to be used in people with compromised immune function. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 6 July 2020. Available from: https://www.tga.gov.au/alert/zostavax-vaccine-0.

TGA. Zostavax vaccine. Safety advisory - risk of infection with the vaccine virus. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 22 December 2020. Available from: https://www.tga.gov.au/alert/zostavax-vaccine-1.

Australasian Society of Clinical Immunology and Allergy (ASCIA). Information updates. Safety Alert: Zostavax Vaccine – NOT to be used in people with compromised immune function. [Internet.] Sydney: ASCIA; 23 December 2020. Available from: https://www.allergy.org.au/about-ascia/info-updates/safety-alert-zostavax-vaccine-not-to-be-used-in-people-with-compromised-immune-function.

Phillips A, Glover C, Leeb A, Cashman P, Fathima P, Crawford N et al. Safety of live attenuated herpes zoster vaccine in Australian adults 70–79 years of age: an observational study using active surveillance. BMJ Open. 2021;11(3):e043880. doi: https://doi.org/10.1136/bmjopen-2020-043880.

AusVaxSafety. AusVax Safety. [Website.] Sydney: NCIRS. Available from: https://ausvaxsafety.org.au/.

ATAGI. Clinical advice. Statement on the clinical use of zoster vaccines in older adults in Australia. Issue date: July 2021. Canberra: Australian Government Department of Health and Aged Care; July 2021. Available from: https://www.health.gov.au/sites/default/files/documents/2021/07/statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia-statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia.docx.

Nelson MR, Britt HC, Harrison CM. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med J Aust. 2010;193(2):110–3.

Australian Government Department of Health and Aged Care. Australian Immunisation Register linked to the Multi-Agency Data Integration Project. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 23 March 2022. Available from: https://www.health.gov.au/initiatives-and-programs/australian-immunisation-register-linked-to-the-multi-agency-data-integration-project.

United Kingdom Health Security Agency. Vaccination against shingles guide. [Internet.] London: Government of the United Kingdom Health Security Agency; 2 December 2021. Available from: https://www.gov.uk/government/publications/shingles-vaccination-for-adults-aged-70-or-79-years-of-age-a5-leaflet/vaccination-against-shingles-guide#who-is-eligible-for-the-vaccine.

Andrews N, Stowe J, Kuyumdzhieva G, Sile B, Yonova I, De Lusignan S et al. Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study. BMJ Open. 2020;10(7):e037458. doi: https://doi.org/10.1136/bmjopen-2020-037458.

Rashid H, Dey A, Manocha R, Tashani M, Macartney K, Beard F. Australia’s national zoster vaccination program: knowledge, attitudes and behaviour of general practitioners. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.59.

TGA. ACV meeting statement, meeting 27, 1 December 2021. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA Advisory Committee on Vaccines; 17 January 2022. Available from: https://www.tga.gov.au/resources/publication/meeting-statements/acv-meeting-statement-meeting-27-1-december-2021.

Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012. BMJ Open. 2018;8(6):e020528. doi: https://doi.org/10.1136/bmjopen-2017-020528.

Parikh R, Widenmaier R, Lecrenier N. A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations. Expert Rev Vaccines. 2021;20(9):1065–75. doi: https://doi.org/10.1080/14760584.2021.1956906.

Stiko beim Robert Koch Institut. Wissenschaftliche Begründung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epidemiologisches Bulletin. 2018;50;541–70. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2018/Ausgaben/50_18.pdf.

Health Council of the Netherlands. Vaccination against shingles. The Hague; Health Council of the Netherlands; 15 July 2019. Available from: https://www.healthcouncil.nl/documents/advisory-reports/2019/07/15/vaccination-of-older-people-against-shingles.

Ministry of Health (Greece). National Vaccination Program for adults 2018–2019. Athens: Ministry of Health; 2018.

Office fédéral de la santé publique. Recommandations de vaccination contre le zona (herpès zoster). Liebefeld: Office fédéral de la santé publique; 2017. Available from: https://www.infovac.ch/docs/public/zona-herpes-zoster/1-recommandations-vaccination-zona.pdf.

Health Service Executive (HSE) National Immunisation Advisory Committee (NIAC). Immunisation Guidelines Chapter 23 Varicella-Zoster. Dublin: HSE/Royal College of Physicians of Ireland; 20 October 2022. Available from: https://www.rcpi.ie/Healthcare-Leadership/NIAC/Immunisation-Guidelines-for-Ireland.

Public Health Agency of Sweden. Shingles vaccine (herpes zoster). [Webpage.] Solna: Socialdepartmentet, Folkhälsomyndigheten; 21 February 2022. Available from: https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/vacciner-a-o/baltros/.

Warrington R, Ismail S, National Advisory Committee on Immunisation. Summary of the NACI Update on Herpes Zoster Vaccines. Can Commun Dis Rep. 2018;44(9):220–5. doi: https://doi.org/10.14745/ccdr.v44i09a06.

Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Recomendaciones de vacunación frente a herpes zóster. Madrid: Government of Spain, Ministry of Health; 25 March 2021. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/docs/HerpesZoster_RecomendacionesVacunacion.pdf.

Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–8. doi: https://doi.org/10.15585/mmwr.mm6703a5.

Australian Government Department of Health and Aged Care. National Immunisation Program Schedule. [Internet.] Australian Government Department of Health and Aged Care; 14 January 2022. Available from: https://www.health.gov.au/health-topics/immunisation/when-to-get-vaccinated/national-immunisation-program-schedule.

European Medicines Agency (EMA). Zostavax: shingles (herpes zoster) vaccine (live). [Webpage.] Amsterdam: EMA; 2 February 2016. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zostavax.

EMA. Shingrix: herpes zoster vaccine (recombinant, adjuvanted). [Webpage.] Amsterdam: EMA; 28 September 2020. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/shingrix.

Bundesministerium Soziales Gesundheit Pflege und Konsumentenschutz (BMSGPK). Impfplan Österreich 2022: Jänner 2022. Vienna: Government of Austria, Federal Ministry of Social Affairs, Health, Care and Consumer Protection (BMSGPK); January 2022. Available from: https://www.paediatrie.at/images/Covid19/impfplan_oesterreich_2022.pdf.

Superior Health Council. Vaccination against herpes zoster virus (Zona). CSS 9209. Brussels: Superior Health Council; July 2017. Available from: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/9209_shc_advice_9209_zonaa5_pdt.pdf.

Cassimos DC, Effraimidou E, Medic S, Konstantinidis T, Theodoridou M, Maltezou HC. Vaccination programs for adults in Europe, 2019. Vaccines. 2020;8(1):34. doi: https://doi.org/10.3390/vaccines8010034.

European Centre for Disease Prevention and Control (ECDC). Vaccine scheduler. Herpes zoster: recommended vaccinations. [Webpage.] Solna: ECDC; 2022. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=51.

Santé Publique France. Calendrier des vaccinations et recommandations vaccinales 2021. [Document.] Paris: Santé Publique France; 11 May 2021.

Sheikh S, Biundo E, Courcier S, Damm O, Launay O, Maes E et al. A report on the status of vaccination in Europe. Vaccine. 2018;36(33):4979–92. doi: https://doi.org/10.1016/j.vaccine.2018.06.044.

Standing Committee on Vaccinations (STIKO). Robert Koch Institut. Immunisation Schedule. Recommendations by the Standing Vaccination Committee (STIKO) at the Robert Koch Institute – 2022. Berlin: Robert Koch Institut; 27 January 2022. Available from: https://www.rki.de/EN/Content/infections/Vaccination/recommandations/04_22_englisch.pdf.

Giuffrida S. Calabria: a successful experience implementing herpes zoster vaccination strategies. Aging Clin Exp Res. 2019;31(3):421–3. doi: https://doi.org/10.1007/s40520-019-01145-2.

Il Direttore Generale Direzione Generale Della Prevenzione Sanitaria. OGGETTO: Aggiornamento sulla vaccinazione contro Herpes zoster. Rome: Italian Government Ministry of Health; 8 March 2021. Available from: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=79080&parte=1%20&serie=null.

National Advisory Committee on Immunization. Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep. 2010;36(ACS-1):1–19. doi: https://doi.org/10.14745/ccdr.v36i00a01.

Ontario Ministry of Health. Transition to publicly funded Shingrix ® vaccine for Ontario’s shingles (herpes zoster) immunization program: information for health care providers. Toronto: Province of Ontario Ministry of Health; 31 May 2021. Available from: https://www.health.gov.on.ca/en/pro/programs/immunization/docs/shingles_hcp_qa_en.pdf.

State of Israel Ministry of Health. Table of vaccines recommended for adults. Jerusalem: State of Israel Ministry of Health; 2014. Available from: https://www.health.gov.il/UnitsOffice/HD/PH/epidemiology/td/docs/370_Adult.pdf.

Choi WS, Choi JH, Kwon KT, Seo K, Kim MA, Lee SO et al. Revised adult immunization guideline recommended by the Korean society of infectious diseases, 2014. Infect Chemother. 2015;47(1):68–79. doi: https://doi.org/10.3947/ic.2015.47.1.68.

Gutiérrez-Robledo LM, Caro-López E, Guerrero-Almeida ML, Dehesa-Violante M, Rodríguez-Noriega E, García-Lara JM et al. Results of the first Mexican Consensus of Vaccination in the Adult. [Article in Spanish.] Gac Méd Méx. 2017;153(2):190–204.

Ministry of Health New Zealand. Appendix 1: The history of immunisation in New Zealand. [Webpage.] Wellington: New Zealand Government Ministry of Health; 20 January 2022. Available from: https://www.health.govt.nz/our-work/immunisation-handbook-2020/appendix-1-history-immunisation-new-zealand.

Tomalin D, Ramsay M. Shingles immunisation programme: introduction of Shingrix letter. [Transcript of correspondence.] London: Government of the United Kingdom, National Health Service/Public Health England; 18 August 2021. Available from: https://www.gov.uk/government/publications/shingles-immunisation-programme-introduction-of-shingrix-letter/shingles-immunisation-programme-introduction-of-shingrix-letter.

Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80–4. doi: https://doi.org/10.15585/mmwr.mm7103a2.

Martins D, McCormack D, Tadrous M, Gomes T, Kwong JC, Mamdani MM et al. Impact of a publicly funded herpes zoster immunization program on the burden of disease in Ontario, Canada: a population-based study. Clin Infect Dis. 2021;72(2):279–84. doi: https://doi.org/10.1093/cid/ciaa014.

Matthews I, Lu X, Dawson H, Bricout H, O’Hanlon H, Yu E et al. Assessing the effectiveness of zoster vaccine live: a retrospective cohort study using primary care data in the United Kingdom. Vaccine. 2018;36(46):7105–11. doi: https://doi.org/10.1016/j.vaccine.2018.08.037.

Walker JL, Andrews NJ, Amirthalingam G, Forbes H, Langan SM, Thomas SL. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine. 2018;36(17):2371–7. doi: https://doi.org/10.1016/j.vaccine.2018.02.021.

Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S et al. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Health. 2018;3(2):e82–90. doi: https://doi.org/10.1016/S2468-2667(17)30234-7.

Downloads

Published

27/04/23

How to Cite

Huang, Yuanfei Anny, Jean Li-Kim-Moy, Sanjay Jayasinghe, Clayton Chiu, Kristine Macartney, Bette Liu, Penelope Burns, Michelle Giles, and Nigel Crawford. 2023. “ATAGI Targeted Review 2022: Vaccination for Prevention of Herpes Zoster in Australia”. Communicable Diseases Intelligence 47 (April). https://doi.org/10.33321/cdi.2023.47.21.

Issue

Vol. 47 (2023)

Section

Review article

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 > >>